Dolores Schendel
Technik-/Wissenschafts-/F&E-Leiter bei MEDIGENE AG
Vermögen: 1 Mio $ am 30.04.2024
Aktive Positionen von Dolores Schendel
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MEDIGENE AG | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2014 | - |
Vorstandsvorsitzender | 31.08.2018 | 24.07.2022 | |
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Vorstandsvorsitzender | - | - |
Karriereverlauf von Dolores Schendel
Ehemalige bekannte Positionen von Dolores Schendel
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Institute of Molecular Immunology | Direktor/Vorstandsmitglied | 01.01.1998 | 01.01.2013 |
European Research Council
European Research Council Investment Trusts/Mutual FundsMiscellaneous The European Research Council is an organization that provides grants for research projects. The organization is based in Brussels, Belgium. As a grantee, individuals are required to submit scientific and financial reports for assessment by ERC Scientific Officers. The organization emphasizes the importance of research ethics and compliance with legislation, disciplinary norms, and protection of research subjects. The responsibility for ethics lies with the individuals conducting the research, while the formal accountability lies with the signatory of the Grant Agreement, the Host Institution. | Corporate Officer/Principal | - | - |
German Cancer Aid | Corporate Officer/Principal | - | - |
Deutsche Forschungsgemeinschaft | Corporate Officer/Principal | - | - |
Medigene Immunotherapies GmbH
Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Vorstandsvorsitzender | 01.05.2014 | - |
Gründer | 01.05.2014 | - | |
Ludwig-Maximilians-Universität München | Corporate Officer/Principal | - | - |
Ausbildung von Dolores Schendel
University of Wisconsin | Doctorate Degree |
Statistik
International
Deutschland | 7 |
Vereinigte Staaten | 3 |
Belgien | 2 |
Operativ
Corporate Officer/Principal | 4 |
Chief Executive Officer | 3 |
Chief Tech/Sci/R&D Officer | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 4 |
Miscellaneous | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
MEDIGENE AG | Health Technology |
Private Unternehmen | 5 |
---|---|
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Health Technology |
European Research Council
European Research Council Investment Trusts/Mutual FundsMiscellaneous The European Research Council is an organization that provides grants for research projects. The organization is based in Brussels, Belgium. As a grantee, individuals are required to submit scientific and financial reports for assessment by ERC Scientific Officers. The organization emphasizes the importance of research ethics and compliance with legislation, disciplinary norms, and protection of research subjects. The responsibility for ethics lies with the individuals conducting the research, while the formal accountability lies with the signatory of the Grant Agreement, the Host Institution. | Miscellaneous |
Institute of Molecular Immunology | |
Medigene Immunotherapies GmbH
Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Health Technology |
German Cancer Aid |
- Börse
- Insiders
- Dolores Schendel
- Erfahrung